Browse all 653 ETFs by category, no search needed
Global 187
US market 62
Country 93
Core UCITS 15
Sector 103
Style & factor 111
Theme 45
Dividend 37
Global X Genomics & Biotechnology (GNOM)Overvalued or undervalued?
Look-through valuation · Sector · Expense ratio 0.47 % · ISIN US37954Y4347
Price history (since 2019)
Monthly close since 2019. Price shows performance, the valuation verdict is in the look-through above.
Top holdings
| Holding | Weight | vs fair value | Quality |
|---|---|---|---|
| Moderna Inc MRNA | 12.2 % | n/a | n/a |
| Twist Bioscience Corp TWST | 6.1 % | n/a | n/a |
| 10X Genomics Inc TXG | 6.0 % | −70.4 % | 64 |
| Illumina Inc ILMN | 5.9 % | +10.0 % | 81 |
| Natera Inc NTRA | 5.3 % | −94.5 % | 40 |
| Guardant Health Inc GH | 5.0 % | n/a | n/a |
| Bio-Techne Corp TECH | 3.4 % | −29.7 % | 78 |
| Genscript Biotech Corp 1548 | 3.4 % | −30.2 % | 55 |
| Qiagen NV QGEN | 3.4 % | −22.8 % | 77 |
| Vertex Pharmaceuticals Inc VRTX | 3.4 % | +12.4 % | 79 |
| Biomarin Pharmaceutical Inc BMRN | 2.8 % | +11.3 % | 69 |
| Caris Life Sciences, Inc. Common Stock CAI | 2.7 % | −78.1 % | 59 |
| Crispr Therapeutics AG CRSP | 2.6 % | −65.6 % | 28 |
| Veracyte Inc VCYT | 2.5 % | +10.0 % | 72 |
| CareDx Inc CDNA | 2.4 % | −79.8 % | 71 |
| BioNTech SE BNTX | 2.3 % | −29.0 % | 50 |
| Arrowhead Pharmaceuticals Inc ARWR | 2.2 % | −52.0 % | 52 |
| Praxis Precision Medicines Inc PRAX | 2.2 % | n/a | n/a |
| Legend Biotech Corp LEGN | 2.0 % | n/a | n/a |
| Eli Lilly and Company LLY | 2.0 % | −41.2 % | 67 |
| Gilead Sciences Inc GILD | 1.7 % | +27.4 % | 81 |
| Beam Therapeutics Inc BEAM | 1.6 % | −58.7 % | 46 |
| BillionToOne, Inc. Class A Common Stock BLLN | 1.6 % | −87.2 % | 59 |
| Sarepta Therapeutics Inc SRPT | 1.5 % | n/a | n/a |
| GeneDx Holdings Corp. WGS | 1.3 % | −82.9 % | 48 |
Fair value and quality per position come from the same valuation as our stock pages. Showing the 25 largest of 50 disclosed positions. "n/a" means the position is not (yet) in our stock universe and does not enter the average.
The 10 most cheaply valued ETFs
Measured against the look-through fair value of the holdings (sufficiently covered funds only). Green means below fair value, red above. Not financial advice.
- 1 KWEB KraneShares CSI China Internet ETF 49.7 % below FV
- 2 CHIQ Global X MSCI China Consumer Disc ETF 49.3 % below FV
- 3 CHIU Global X MSCI China Utilities ETF 45.9 % below FV
- 4 MCHI iShares MSCI China ETF 36.3 % below FV
- 5 FLCH Franklin FTSE China ETF 35.9 % below FV
- 6 FDNI First Trust Dow Jones International Internet ETF 28.4 % below FV
- 7 FCFY First Trust S&P 500 Diversified Free Cash Flow ETF 26.1 % below FV
- 8 ITB iShares U.S. Home Construction ETF 23.0 % below FV
- 9 FDEM Fidelity® Emerging Markets Multifactor ETF 17.0 % below FV
- 10 XLC Communication Services Select Sector SPDR® Fund 16.2 % below FV
Frequently asked about GNOM
Is GNOM overvalued?
What is the fair value of GNOM?
How do you calculate the fair value of an ETF?
Which stocks drive the valuation of GNOM?
What is the expense ratio of GNOM?
How we value this ETF
An ETF has no fair value of its own like a single stock. We build it bottom up: every holding has a fair value and a quality score on our pages. Weighted by portfolio share, that gives Global X Genomics & Biotechnology ETF an average of how cheap or expensive its companies currently sit versus fair value, and how high their average quality is.
As of: Oct 26, 2026
The look-through is a computed summary of public fundamentals and is no substitute for your own research.